| Preview | Issue Date | Title | Author(s) |
| 2011 | Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo | Zinonos, I.; Labrinidis, A.; Lee, M.; Liapis, V.; Hay, S.; Ponomarev, V.; Diamond, P.; Findlay, D.; Zannettino, A.; Evdokiou, A. |
| 2009 | Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma | Labrinidis, A.; Diamond, P.; Martin, S.; Hay, S.; Liapis, V.; Zinonos, I.; Sims, N.; Atkins, G.; Vincent, C.; Ponomarev, V.; Findlay, D.; Zannettino, A.; Evdokiou, A. |
| 2009 | Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer | Zinonos, I.; Labrinidis, A.; Lee, M.; Liapis, V.; Hay, S.; Ponomarev, V.; Diamond, P.; Zannettino, A.; Findlay, D.; Evdokiou, A. |
| 2008 | Does Apo2LTRAIL play any physiologic role in osteoclastogenesis? | Labrinidis, A.; Liapis, V.; Thai, L.; Atkins, G.; Vincent, C.; Hay, S.; Sims, N.; Zannettino, A.; Findlay, D.; Evdokiou, A. |
| 2002 | Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis | Atkins, G.; Bouralexis, S.; Evdokiou, A.; Hay, S.; Labrinidis, A.; Zannettino, A.; Haynes, D.; Findlay, D. |
| 2003 | Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis | Evdokiou, A.; Labrinidis, A.; Bouralexis, S.; Hay, S.; Findlay, D. |
| 2003 | Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy | Bouralexis, S.; Findlay, D.; Atkins, G.; Labrinidis, A.; Hay, S.; Evdokiou, A. |
| 2011 | RECK in osteosarcoma: A novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model | Clark, J.; Akiyama, T.; Thomas, D.; Labrinidis, A.; Evdokiou, A.; Galloway, S.; Kim, H.; Dass, C.; Choong, P. |
| 2004 | Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin | Bouralexis, S.; Clayer, M.; Atkins, G.; Labrinidis, A.; Hay, S.; Graves, S.; Findlay, D.; Evdokiou, A. |
| 2006 | The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL | Butler, L.; Liapis, V.; Bouralexis, S.; Welldon, K.; Hay, S.; Thai, L.; Labrinidis, A.; Tilley, W.; Findlay, D.; Evdokiou, A. |
| 2002 | Zoledronate is anabolic for human osteoblast-like cells | Atkins, G.; Pan, B.; Findlay, D.; To, L.; Evdokiou, A.; Labrinidis, A.; Bouralexis, S.; Zannettino, A.; American Society for Bone and Mineral Research. Conference (24th : 2002 : San Antonio, Texas) |
| 2009 | Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model | Labrinidis, A.; Hay, S.; Liapis, V.; Ponomarev, V.; Findlay, D.; Evdokiou, A. |
| 2010 | Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model | Labrinidis, A.; Hay, S.; Liapis, V.; Findlay, D.; Evdokiou, A. |
